Compare Consolidated Edison, Inc. (ED) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs Revvity Inc — how do they compare? Consolidated Edison, Inc. trades at $106.27 (market cap $39.20B), while Revvity Inc trades at $154.72 (market cap $16.98B). The key difference: Consolidated Edison, Inc. is far larger — about 2.3× Revvity Inc's market cap, and Consolidated Edison, Inc. pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Consolidated Edison, Inc. for 75 Days and Revvity Inc for 12 Days on average.
| ED | RVTY | |
|---|---|---|
Market Cap | $39.20B | $16.98B |
Volume | 2,142,900 | 1,456,900 |
Sector | Utilities | Health |
52-Week High | $115.46 | $157.36 |
52-Week Low | $95.37 | $82.26 |
Typical Hold Time | 75 Days | 12 Days |
Enterprise Value | $66.05B | $19.30B |
Dividend Yield | 3.31% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $105.94, up 1.23% today, near the consensus price target of $106.33. The stock shows a mixed technical picture with a bullish overall signal but bearish moving averages, while fundamentals reflect steady utility performance with 2025 revenue of $16.92B and net income of $2.02B. Recent news highlights its $24.8B economic impact in New York and upcoming investor webcast, reinforcing its stable dividend aristocrat status.
ED offers a defensive investment with a reliable dividend and moderate growth, but faces risks from high debt levels and interest expenses. Analyst sentiment is cautious with 62.96% hold ratings, suggesting limited near-term upside despite solid cash flow generation. The stock's appeal lies in its income stability amid economic uncertainty, though execution on capital expenditures remains key to sustaining growth.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
